Brain Tumour

BRAIN TUMOURS

About

The brain tumour group focuses on the preclinical and clinical evaluation of new radiopharmaceuticals for nuclear medicine diagnostics of patients with brain tumours (e.g., gliomas and metastases) using positron emission tomography (PET) and the correlation and investigation of advanced magnetic resonance imaging (MRI) techniques. This includes the assessment of amino acid uptake in brain tumours, along with modern developments in functional MRI, including structural and functional connectivity and the clinical application of correlative hybrid PET/MRI for diagnosis, therapy planning and therapy response assessment in brain tumour patients.

Further, to enhance the potential of PET/MRI for brain tumour diagnostics, quantitative image analysis methods, including artificial intelligence technologies such as radiomics and deep learning, are being developed and evaluated.

Additional fields of specialist interest include the evaluation of the therapeutic effects of novel amyloid-β binding peptide ligands for neurodegenerative diseases such as Alzheimer’s using behavioural tests, autoradiography, as well as PET and MRI.

Research Topics

Amino acid PET
Advanced MRI
Hybrid PET/MRI
Quantitative image analysis & artificial intelligence
Functional connectivity in brain tumour patients
Preclinical brain tumour models
Neurodegenerative diseases

Contact

Prof. Dr. med. Karl-Josef Langen

INM-4

Building 15.2 / Room 372

+49 2461/61-5900

E-Mail

HIGHLIGHTS

AI-based tumour detection and segmentation for an automated assessment of therapy response

A new artificial intelligence tool provides a fully automated, easy-to-use and objective way to detect and evaluate brain tumors. Developed for use with amino acid PET scans, the deep learning-based segmentation algorithm can assess brain tumor patients’ response to treatment with quality comparable to that of an experienced physician, but in a fraction of the time.

Press release in SNMMI

Gutsche R, Lowis C, Ziemons K, Kocher M, Ceccon G, Régio Brambilla C, Shah NJ, Langen KJ, Galldiks N, Isensee F, Lohmann P. Automated Brain Tumor Detection and Segmentation for Treatment Response Assessment Using Amino Acid PET. J Nucl Med. 2023 Oct;64(10):1594-1602. doi: 10.2967/jnumed.123.265725. Epub 2023 Aug 10. PMID: 37562802.

Correlative spectroscopic MR imaging and FET PET in brain tumours using hybrid PET-MRI

Both FET PET and spectroscopic MR imaging (MRSI) can identify brain tumor tissue with higher accuracy than conventional MRI. In a hybrid PET-MRI study on 30 untreated patients with various brain tumors, FET enhancement was compared with the MR spectroscopic result. The analysis was carried out at the anatomical coordinates at which control results from stereotactic biopsies were determined as part of the study. There was a slightly higher accuracy of FET uptake compared to the choline/N-acetyl aspartate ratio.

Mauler, Jörg, Philipp Lohmann, Andrew A. Maudsley, Sulaiman Sheriff, Moritz Hoevels, Anna-Katharina Meissner, Christina Hamisch, et al. ‘Diagnostic Accuracy of MR Spectroscopic Imaging and 18 F-FET PET for Identifying Glioma: A Biopsy-Controlled Hybrid PET/MRI Study’. Journal of Nuclear Medicine, 26 October 2023, jnumed.123.265868.